… better understand and find treatments for eye conditions … identify solutions for treating conditions like retinal degeneration or physical … at where regeneration and development diverge and are … genetic mechanisms behind mollusk development." For each …

… trial for OCU410ST - a modifier gene therapy candidate being developed … for approvals.” "Treating the first patient with … vision with no approved treatment options. The encouraging … eye disorder that causes retinal degeneration and vision loss. Stargardt …

… II/III GARDian3 trial of modifier gene therapy candidate … that will not receive the treatment. GARDian3’s primary goal … leading to vision loss and retinal degeneration. In March 2025, Ocugen … Phase I trial of OCU200, a fusion protein for treating diabetic …

… trial. OCU410ST, which is being developed by Ocugen, is a possible treatment … eye disorder that causes retinal degeneration and vision loss in … executives from Ocugen. The FDA has granted a Rare Pediatric … phase 1/2 trial to treat dry age-related macular …

… funding agreement with the Retinal Degeneration Fund (RD Fund), … is currently in preclinical development, targeting a rod- … for which no approved treatments currently exist. Strategic Partnership … asset towards Investigational New Drug enabling studies. We …

… trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed … for approvals.” "Treating the first patient with … vision with no approved treatment options. The encouraging … eye disorder that causes retinal degeneration and vision loss. …

… an agreement with the Retinal Degeneration Fund (RD Fund), … gene therapies are developed to treat patients with retinitis pigmentosa … asset towards Investigational New Drug enabling studies. We are … virus vector for the treatment of MERTK-associated inherited …

… US Food and Drug Administration (FDA) has granted fast … hasten the development and review of new drugs that … delivery of significant new medications to patients, encompassing … treating patients with neovascular wet AMD. AMD is a progressive retinal degeneration …

… phase 2b RESTORE clinical trial (NCT04945772), which met … step toward developing a universal treatment for retinal … FDA for MCO-010, the first gene-agnostic therapy to treat … vision in patients with severe retinal degeneration, Molecular Therapy (2025), …

… vectorized therapy designed to treat dry AMD/GA … retinal degeneration. Details of the Phase 1 Study The PST-611-CT1 trial … trials: “Having pioneered the development of the electro-transfection … to become a major treatment option for these patients.” …